Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ: COSM), a globally diversified healthcare company, has announced a significant valuation of its real estate assets, which is estimated at approximately $15 million. This figure surpasses the company’s current market capitalization of around $13.5 million as of February 17, 2026. Cosmos Health is evaluating various monetization options to address the notable discount to its book value of $23.1 million as of Q3 2025.
The company’s primary real estate holdings include the Cana Laboratories manufacturing facility and the CosmoFarm logistics center, both located in Athens, Greece. The Cana facility spans about 54,000 square feet with additional buildable capacity, positioned in a prime area that offers high commercial viability. The CosmoFarm site, covering approximately 29,100 square feet in a densely populated area, serves as a logistics hub, utilizing advanced automation for efficient operations.
Given the favorable conditions in the Greek property market—where residential and commercial real estate have surpassed previous peak values—Cosmos Health illuminates the strategic potential of its real estate assets. CEO Greg Siokas underscored the disparity between the company’s market valuation and its actual asset worth, emphasizing a focus on unlocking intrinsic value for shareholders. The options under consideration for monetization could include outright sales, joint ventures, or sale-leaseback transactions, with proceeds potentially directed toward debt reduction, growth initiatives, or other shareholder value-boosting actions.
As the company continues to innovate in pharmaceuticals and nutraceuticals while expanding into telehealth, its real estate assets offer a strategic avenue to enhance financial flexibility and support its overall business objectives.
MWN-AI** Analysis
**Market Analysis and Advice on Cosmos Health Inc. (NASDAQ:COSM)**
As of mid-February 2026, Cosmos Health Inc. stands at an intriguing intersection of value and opportunity. The company's significant real estate assets, estimated at approximately $15 million, vastly exceed its current market capitalization of about $13.5 million. This discrepancy suggests a market undervaluation, presenting a potential investment opportunity for discerning stakeholders.
The company's properties, including the Cana Laboratories manufacturing facility and the CosmoFarm logistics center, not only represent substantial intrinsic value but also offer potential for strategic monetization. The favorable conditions in the Greek real estate market, with property prices experiencing sustained growth, further enhance the appeal of these assets. With these facilities debt-free and strategically located in key urban areas of Athens, Cosmos Health may capitalize on their value through various pathways: outright sales, joint ventures, or leaseback transactions.
Investors should cautiously consider Cosmos Health at its current trading levels. The company’s valuation reflects a significant discount to book value, suggesting that sensible monetization of real estate could yield proceeds comparable to its existing public float. Should the company pursue these monetization options effectively, it could bolster its financial position—possibly fueling growth initiatives or enhancing shareholder value through planned reinvestments.
However, potential investors must be mindful of inherent risks, including overall market conditions and execution risks associated with the realization of strategic plans. The volatility in global markets, particularly in response to external factors such as geopolitical tensions, may also impact operations.
In summary, Cosmos Health presents a compelling opportunity for value investors willing to monitor upcoming developments closely. The firm’s strategic reevaluation of its assets could unlock significant shareholder value, making it a stock worth watching in the evolving healthcare landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value.
Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company’s Cana Laboratories (“Cana”) manufacturing facility and CosmoFarm logistics center at approximately $15 million. This estimate reflects the value of the land and buildings only and excludes the value of machinery and equipment housed within the facilities.
The estimated value reflects favourable macro conditions in the Greek property market. According to Bank of Greece data, residential property prices in Greece have surpassed their 2008 pre-financial crisis peak and reached record highs. Commercial real estate, including office, retail, and logistics segments, has also experienced sustained pricing and rental growth in key urban centers, particularly in Athens.
The estimated fair market value of the Company’s real estate assets exceeds the Company’s current market capitalization, which stood at approximately $13.5 million as of the close of trading on February 17, 2026.
Cana Laboratories – Neo Iraklio, Athens
The Cana property comprises a land plot of approximately 54,000 square feet and a total constructed building area of approximately 35,700 square feet. Based on the applicable building coefficient, the site allows for additional buildable capacity, subject to zoning and regulatory approvals. The property is wholly owned by the Company and is free of any mortgage or other encumbrances.
It is strategically located in Neo Iraklio, a well-established northern suburb of Athens with strong residential density and developed commercial activity. The property offers direct access to Attiki Odos, one of the primary highway arteries serving the greater Athens metropolitan area, and is within a short drive of Athens International Airport, central Athens, and surrounding business districts. It is also located just minutes from The Mall Athens, one of the largest enclosed shopping malls in Greece. Beyond its current pharmaceutical manufacturing and research and development use, the property’s location supports meaningful alternative use potential.
CosmoFarm Logistics Center – Peristeri, Athens
The CosmoFarm facility is wholly owned by the Company, consists of approximately 29,100 square feet, and is located in Peristeri, a densely populated municipality in western Athens with strong infrastructure and transport connectivity. The property currently operates as a pharmaceutical wholesale and distribution hub for Cosmos Health’s logistics subsidiary, CosmoFarm, and incorporates advanced automation and robotic systems supporting inventory management and order execution.
Strategic Optionality
At the current trading levels, the Company’s market capitalization reflects a significant discount to its reported book value (stockholders’ equity) of $23.1 million as of Q3 2025. In this context, the estimated value of the Company’s real estate portfolio represents capital that is substantial relative to its public equity value. Monetization, if pursued at or near estimated fair market value, could generate proceeds comparable to, or exceeding, the Company’s current public float.
Potential alternatives under consideration may include an outright sale, joint venture structures, sale leaseback transactions, or other strategic arrangements, subject to market conditions. Proceeds, if realized, may be used for debt reduction, reinvestment into core growth initiatives, acquisitions, or shareholder value-enhancing actions.
Greg Siokas, CEO of Cosmos Health, stated: “We believe there is a meaningful disconnect between our current valuation and the intrinsic value of our assets, with our real estate assets alone worth more than our entire market capitalization. These strategically located properties provide meaningful financial optionality. As a diversified, vertically integrated pharmaceutical company, we have a clear mission in the healthcare space. If monetizing non-core real estate assets can unlock substantial value, we will evaluate such opportunities carefully and decisively, and act accordingly.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/270cc392-f5ed-4611-a3af-48bc959deccd
https://www.globenewswire.com/NewsRoom/AttachmentNg/50e6cce1-f53a-40ac-8380-2ae0c0cb42a3
FAQ**
How does Cosmos Holdings Inc. COSM plan to capitalize on the strategically advantageous locations of its real estate assets in Greece to enhance shareholder value through potential monetization options?
What specific strategic options is Cosmos Holdings Inc. COSM considering for the monetization of their real estate portfolio, and how might these impact the company's financial future?
With the reported market capitalization of Cosmos Holdings Inc. COSM below the estimated combined fair market value of its real estate, how does management intend to address this valuation discrepancy to attract investor interest?
How does Cosmos Holdings Inc. COSM aim to leverage proceeds from potential real estate sales or joint ventures to fund growth initiatives and enhance overall shareholder value?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Holdings Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
-3.27% G/L:
$0.37 Last:
279,236 Volume:
$0.381 Open:
